Astrazeneca hopes that its new COPD triplet can gain share from Glaxosmithkline’s rival, but it is not planning a price war.
Pfizer launches an $11.4bn bid for the prolific originator of small molecules, and predicts blockbuster sales in colorectal cancer to help justify the price.
The company needed a hit in its spine trial, and it claims to have got one.
With the company’s Molgradex failing to beat standard of care in a rare lung disorder, the premise behind this project looks questionable.
Achieve Life Sciences gets a reality check despite largely positive smoking cessation data.
As placebo outperforms Cymabay’s seladelpar attention turns to the pivotal trial of Genfit’s elafibranor.
The iLet system showed decent blood sugar control in its first trial, but the highly automated system is far from proven.
The cystic fibrosis player does deals with Crispr and Exonics to launch itself into a highly competitive rare disease area.
Europe and the US approvals of the ReStore device have arrived within a week; now the company must deliver commercially.